ZJYL ZJYL
Company Profile ↓Company Overview
ZJYL (ZJYL) is a publicly traded company listed on with a market capitalization of $15.58M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 9.9.
Recent Developments
- Sep 2025 Revenue of $20.69M (-12.0% YoY); net profit $1.19M.
- Trailing 12 Months Year-on-year growth — revenue -12.0%, earnings -67.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.5%, profit CAGR -23.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.53% |
| 1 Year: | -11.98% |
Compounded Profit Growth
| 5 Years: | -23.93% |
| 1 Year: | -67.59% |
Stock Price Performance
| 1 Year: | -83.02% |
| 6 Months: | -21.03% |
| 3 Months: | -16.03% |
| 1 Month: | -41.12% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.72 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -23.9% CAGR over 5 years.
- Trading 83.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Revenue | - | 19.19M | 19.82M | 23.50M | 20.69M |
| Cost of Revenue | - | 12.99M | 13.04M | 14.00M | 14.64M |
| Gross Profit | - | 6.20M | 6.78M | 9.50M | 6.04M |
| Operating Expenses | - | 4.07M | 3.92M | 5.86M | 5.44M |
| Operating Income | - | 2.13M | 2.87M | 3.64M | 608.18K |
| EBITDA | - | 2.49M | 3.09M | 3.98M | 958.86K |
| Interest Expense | 9.49K | - | - | - | - |
| Pretax Income | - | 2.74M | 3.22M | 4.18M | 1.60M |
| Tax Provision | - | 36.11K | 343.71K | 763.88K | 214.57K |
| Net Income | - | 2.71M | 2.88M | 3.68M | 1.19M |
| Diluted EPS | - | 0.36 | 0.40 | 0.40 | 0.20 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 20.94M | 32.90M | 45.80M | 53.37M |
| Current Assets | - | 18.90M | 31.12M | 42.82M | 44.14M |
| Cash & Equivalents | - | 4.79M | 6.93M | 8.14M | 7.46M |
| Inventory | - | 6.72M | 5.05M | 5.17M | 4.92M |
| Receivables | - | 4.08M | 4.23M | 8.46M | 5.91M |
| Total Liabilities | - | 5.70M | 8.92M | 17.25M | 23.80M |
| Current Liabilities | - | 5.70M | 8.92M | 17.15M | 23.80M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | 4.11M | 11.60M | 18.91M |
| Total Equity | - | 15.24M | 23.98M | 28.82M | 29.64M |
| Shares Outstanding | - | 7.75M | 7.80M | 7.83M | 7.83M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 1.58M | 3.11M | -1.21M | 2.90M |
| Investing Cash Flow | - | -120.90K | -7.73M | -9.51M | -10.79M |
| Financing Cash Flow | - | 121.86K | 6.91M | 11.65M | 7.35M |
| Capital Expenditure | - | -40.17K | -113.94K | -1.12M | -6.63M |
| Free Cash Flow | - | 1.54M | 2.99M | -2.33M | -3.73M |
| Net Change in Cash | - | 1.58M | 2.29M | 933.04K | -534.91K |
Ratios (Annual)
Figures in %.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 32.3% | 34.2% | 40.4% | 29.2% |
| Operating Margin % | - | 11.1% | 14.5% | 15.5% | 2.9% |
| Net Margin % | - | 14.1% | 14.5% | 15.6% | 5.8% |
| ROE % | - | 17.8% | 12.0% | 12.8% | 4.0% |
| ROCE % | - | 14.0% | 12.0% | 12.7% | 2.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZJYL
Jin Medical International Ltd. Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that it ha…
JIN MEDICAL INTERNATIONAL LTD. Reports First Half of Fiscal Year 2026 Financial Results
JIN MEDICAL INTERNATIONAL LTD. (Nasdaq: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment in China, today announced i…
Jin Medical International Ltd. Announces 1-for-20 Share Combination as Part of Strategic Nasdaq Compliance Initiative
Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that its B…
Jin Medical CEO Fireside Chat
Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment hosted a CEO Fireside Chat on February 2, 2026 where t…
Jin Medical International Ltd. To Host Management Fireside Chat
Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment in China, announced today that its Chief Executive Of…
Jin Medical International Ltd. Management Plans For Fireside Chat
Changzhou, China, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (NASDAQ: ZJYL) (“Jin Medical”, and together with all its subsidiaries, the ”Company”), a NASDAQ-listed leading provider of rehabilitation medical equipment i…
ZJYL — Frequently Asked Questions
What is the current share price of ZJYL?
As of 2026-09-16 18:39 PDT, ZJYL trades at $1.99 on NASDAQ/NYSE. Its 52-week range is $1.81 to $11.76.
What is the market capitalisation of ZJYL?
ZJYL has a market capitalisation of $15.58M on NASDAQ/NYSE.
What is the P/E ratio of ZJYL?
ZJYL trades at a trailing price-to-earnings (P/E) ratio of 9.95. Its price-to-book (P/B) ratio is 0.53.
What is the return on equity (ROE) of ZJYL?
ZJYL has a return on equity (ROE) of 4.02%. Its return on capital employed (ROCE) is 2.06%.
Is ZJYL a good stock to buy?
This page provides a data-driven analysis of ZJYL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.